AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure target discovered by BenevolentAI (AMS: BAI), a UK-based precision drug design company. This milestone achievement marks a significant step in their ongoing partnership, which was initially established in 2019 with a focus on idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). The collaboration was later expanded in 2022 to encompass heart failure and systemic lupus erythematosus (SLE), broadening the scope of their joint research efforts.- Flcube.com
Recent news:
-
Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation -
Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation -
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline -
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies -
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
